HC Wainwright Issues Negative Estimate for CDTX Earnings

Cidara Therapeutics, Inc. (NASDAQ:CDTX) – Equities research analysts at HC Wainwright cut their Q1 2025 earnings estimates for Cidara Therapeutics in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst E. Arce now anticipates that the biotechnology company will earn ($5.45) per share for the quarter, down from their previous forecast of ($5.13). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Cidara Therapeutics’ current full-year earnings is ($8.74) per share. HC Wainwright also issued estimates for Cidara Therapeutics’ Q2 2025 earnings at ($1.08) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($1.34) EPS, FY2025 earnings at ($7.12) EPS, FY2026 earnings at ($14.64) EPS, FY2027 earnings at ($16.66) EPS and FY2028 earnings at ($4.73) EPS.

Cidara Therapeutics (NASDAQ:CDTX) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($5.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.28) by ($0.10). Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 69.64%.

Several other brokerages have also recently commented on CDTX. Cantor Fitzgerald upgraded shares of Cidara Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 5th. WBB Securities increased their target price on shares of Cidara Therapeutics from $40.00 to $45.00 and gave the company a “strong-buy” rating in a research note on Thursday, December 5th. Citigroup began coverage on shares of Cidara Therapeutics in a research report on Wednesday. They issued an “outperform” rating on the stock. Royal Bank of Canada began coverage on Cidara Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $34.00 price objective for the company. Finally, Citizens Jmp began coverage on Cidara Therapeutics in a research report on Wednesday. They set an “outperform” rating and a $46.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $39.14.

Cidara Therapeutics Stock Performance

Shares of CDTX stock opened at $23.00 on Wednesday. Cidara Therapeutics has a 1 year low of $10.00 and a 1 year high of $28.42. The business’s fifty day moving average is $22.35 and its 200-day moving average is $17.64. The stock has a market cap of $162.08 million, a PE ratio of -0.90 and a beta of 0.88.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. purchased a new position in Cidara Therapeutics during the 4th quarter valued at about $56,000. Point72 Asset Management L.P. acquired a new stake in shares of Cidara Therapeutics during the fourth quarter worth approximately $165,000. OMERS ADMINISTRATION Corp purchased a new position in Cidara Therapeutics during the fourth quarter valued at approximately $339,000. Jane Street Group LLC acquired a new position in Cidara Therapeutics in the 4th quarter valued at approximately $342,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Cidara Therapeutics during the 4th quarter valued at $419,000. Hedge funds and other institutional investors own 35.82% of the company’s stock.

About Cidara Therapeutics

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.